U.S. National Institutes of Health Conducts Tests on Zecotek’s Green Fiber Laser
Vancouver, BC, June 4, 2008 - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I)is pleased to announce that the National Cancer Institute, a division of the U.S. National Institutes of Health (NIH), recently conducted tests on its proprietary Green Fiber Laser (GFL-550) in flow cytometry applications. The GFL-550’s performance and unique wavelength of 550nm were presented in a paper by Dr. William Telford, Head of the Flow Cytometry Core Laboratory at the National Cancer Institute/NIH at the 24th International Congress of the International Society for Analytical Cytometry, held in Budapest, Hungary May 17-21, 2008.
“Until now a 550nm solution did not exist,” said Dr. William Telford. “The wavelength range that Zecotek’s GFL lasers provide could be ideal for this application. I think the laser confocal microscope community will also be very enthusiastic about being able to choose any wavelength in this range for their systems”.
“The 532nm solid-state laser has become the ubiquitous compromise solution in flow cytometry and confocal microscopy,” said Dr. Faouzi Zerrouk, Chairman and CEO of Zecotek Photonics. “The U.S. National Institutes of Health has shown that our GFL-550 laser meets all performance criteria and therefore is well positioned as the replacement of choice for the 532nm laser.”
Zecotek’s GFL-550 laser successfully met all of the National Cancer Institutes’ performance specifications, notably emitting at a wavelength of 550nm. Specific fluorescent probes can be excited more efficiently at the 550nm wavelength which improves accuracy and broadens the use of flow cytometry in immunology, hematology, transplantations and biomedical research. In addition to 550nm, Zecotek’s GFL series provides wavelengths in the range 515 to 560nm which is optimal for bio-instrumentation, medical, material processing and fundamental research applications.
The GFL series will be manufactured by Fujikura of Japan under the two companies’ joint manufacturing agreement. To learn more about the fiber laser market and the competitive advantages of Zecotek’s Green Fiber Laser and CW Blue-Green Fiber Lasers operating in the range of 450 – 570nm Fiber Lasers, please visit www.zecotek.com/495/1093/.
Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing leading-edge products: crystals, photo detectors, lasers, imaging and 3D display technologies, for medical, biotech, industrial, nanotech and atomic/molecular science applications. Founded in 2003, the company has three distinct operating divisions: Laser Systems, Imaging Systems and 3D Display Systems and labs located in Canada, the United States, Singapore, Malaysia and Russia. Zecotek commercializes its novel, patented and patent-pending photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders. For more information, please visit Zecotek Photonics.
This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
For product and technical information please contact:
Zecotek Photonics Inc.
SUSANA MENDEZ ALCALA
T: (604) 827-5232
For corporate information please contact:
Zecotek Photonics Inc.
CFO; VP Corporate Development
T: (604) 827-5203
For investor information please contact:
Caliber Capital & Communications
T: (778) 327-6678
E: [email protected]
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.